North American Acute Coronary Syndrome (ACS) Reflective III Pilot
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Coronary Syndrome
- Dyslipidemias
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The main objectives are: To identify and describe post-ACS patients who do not achieve guideline-recommended LDL-C "target" (<1.8 mmol/L in Canada, >50% LDL-C lowering on high-intensity statin in the U.S.); To identify opportunities where PCSK9 inhibitor therapy may be of potential benefit in the ma...
The main objectives are: To identify and describe post-ACS patients who do not achieve guideline-recommended LDL-C "target" (<1.8 mmol/L in Canada, >50% LDL-C lowering on high-intensity statin in the U.S.); To identify opportunities where PCSK9 inhibitor therapy may be of potential benefit in the management of post-ACS patients to achieve guideline-recommended LDL-C goal by 1 year follow-up; and, To determine reasons why physicians are not prescribing guideline-recommended LDL-C lowering therapies and/or patients are not achieving guideline-recommended LDL-C goals.
Tracking Information
- NCT #
- NCT03994575
- Collaborators
- Sanofi
- Investigators
- Principal Investigator: Shaun G Goodman, MD, MSc Co-Chair, Canadian Heart Research Centre
Get Well Soon